risedronate sodium

Medeoros is a brand name for **risedronate sodium**, a nitrogen-containing pyridinyl bisphosphonate marketed by the Italian company **Fenix Pharma**. It is primarily indicated for the treatment and prevention of osteoporosis in postmenopausal women and men to reduce the risk of vertebral and non-vertebral fractures. It is also used in the management of Paget's disease of bone. Risedronate works by binding to hydroxyapatite crystals in the bone matrix and inhibiting the enzyme **farnesyl pyrophosphate synthase (FPPS)** within osteoclasts. This inhibition disrupts the mevalonate pathway, preventing the prenylation of small GTP-binding proteins essential for osteoclast function and survival, thereby reducing bone resorption and increasing bone mineral density.

Brand names

Medeoros

Other names

risedronaterisedronic acidrisedronato sodico